Pharmacokinetics of long-acting capsule of carteolol hydrochloride in a repeated study.
Masaaki Odomi, Kimiyo MATSUURA, Takefumi Shimizu
Abstract
Open-access reader
Masaaki Odomi, Kimiyo MATSUURA, Takefumi Shimizu
Abstract
Open-access reader
Pharmacokinetics of long-acting (LA) capsule of carteolol hydrochloride were investigatedin healthy adult male volunteers. The LA group received 15 mg/person once daily whilethe comparison group received conventional tablets (CT), 5 mg/person, three times a day, for 9 days of repeated administration.The plasma concentrations of both the LA and CT groups reached a steady-state on Day3.Although the pharmacokinetic parameters, AUC, Cmax, Cmin, and Cmax/Cmin in the steadystaterevealed no significant differences between the two groups, t1/2 was significantlydifferent between LA (9.3hr), and CT (6.9hr).The plasma concentration profile on the LA repeated adminitsration corresponded wellto the prediction curves estimated from the LA single administration study. T1/2 in thesteady-state of LA dosing was quite similar to that of a single adminitsration of LA. Thesefacts reveal that the prolongation of plasma concentration maintained by LA administrationdid not cause any accumulation of carteolol nor any change in the pharmacokinetics.In conclusion, a once-daily administration by LA capsule is proposed as being clinicallyuseful.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Pharmacokinetics of long-acting (LA) capsule of carteolol hydrochloride were investigatedin healthy adult male volunteers. The LA group received 15 mg/person once daily whilethe comparison group received conventional tablets (CT), 5 mg/person, three times a day, for 9 days of repeated administration.The plasma concentrations of both the LA and CT groups reached a steady-state on Day3.Although the pharmacokinetic parameters, AUC, Cmax, Cmin, and Cmax/Cmin in the steadystaterevealed no significant differences between the two groups, t1/2 was significantlydifferent between LA (9.3hr), and CT (6.9hr).The plasma concentration profile on the LA repeated adminitsration corresponded wellto the prediction curves estimated from the LA single administration study. T1/2 in thesteady-state of LA dosing was quite similar to that of a single adminitsration of LA. Thesefacts reveal that the prolongation of plasma concentration maintained by LA administrationdid not cause any accumulation of carteolol nor any change in the pharmacokinetics.In conclusion, a once-daily administration by LA capsule is proposed as being clinicallyuseful.
Key concepts: Cmin, Pharmacokinetics, Cmax, Capsule, Pharmacology, Medicine, Dosing, Plasma concentration